Biodesix Announces First Quarter 2025 Results and Highlights

Core Insights - Biodesix, Inc. reported a total revenue of $18.0 million for Q1 2025, marking a 21% increase compared to Q1 2024 [1][3] - The company achieved gross margins of 79.4% in Q1 2025, an improvement from 78.6% in the prior year [3] - Net loss for Q1 2025 was $11.1 million, which is an 18% improvement over the same period last year [3][10] - The revenue guidance for 2025 has been updated to a range of $80-85 million [4] Financial Performance - Diagnostic Testing revenue reached $16.3 million in Q1 2025, an 18% increase year-over-year, driven by a rise in total tests delivered [3] - Development Services revenue surged by 61% to $1.7 million in Q1 2025 compared to the prior year [3] - Operating expenses for Q1 2025 were $23.4 million, a 3% increase from the previous year, primarily due to a $900 thousand rise in Research and Development costs [3] Strategic Initiatives - The company has restructured its sales team into a territory-based model to enhance access to patients with lung nodules, following a successful commercial pilot [2] - Biodesix aims to achieve Adjusted EBITDA positivity in Q4 2025, despite being approximately one quarter behind in its commercial plan [2][4] - The company strengthened its cash position by drawing down $10 million from its term loan facility, raising its pro forma cash balance to $27.6 million [2][10]